The finding, published in the journal Cancer Research, provides important insight into the development of this disease.
“Neuroblastoma is a highly aggressive cancer that nearly exclusively affects young children,” said researcher Paul Galardy at Mayo Clinic in the US, adding that, despite the use of multiple treatments approaches many children die of this disease every year.
To identify new therapeutic approaches, the team examined the role of a set of enzymes known as deubiquitinating enzymes (DUB) in this disease. They chose this family of enzymes because they could be targeted using drug therapy.
“We used a computational approach to determine the effect of too much or too little of a gene on the outcome of a variety of human cancers